vs
Side-by-side financial comparison of Bausch Health Companies Inc. (BHC) and Burlington Stores, Inc. (BURL). Click either name above to swap in a different company.
Bausch Health Companies Inc. is the larger business by last-quarter revenue ($2.8B vs $2.7B, roughly 1.0× Burlington Stores, Inc.). Burlington Stores, Inc. runs the higher net margin — 3.9% vs -3.7%, a 7.6% gap on every dollar of revenue. On growth, Bausch Health Companies Inc. posted the faster year-over-year revenue change (9.3% vs 7.1%). Bausch Health Companies Inc. produced more free cash flow last quarter ($403.0M vs $-109.6M). Over the past eight quarters, Bausch Health Companies Inc.'s revenue compounded faster (14.0% CAGR vs -6.9%).
Bausch Health Companies Inc. is a global, diversified American-Canadian pharmaceutical company. Its global corporate headquarters are located in Laval, Quebec, Canada, and its U.S. headquarters are in Bridgewater, New Jersey. It develops, manufactures and markets a range of pharmaceutical products in gastroenterology, hepatology, neurology, dermatology, dentistry, medical aesthetics, and international pharmaceuticals. Bausch Health manufactures and markets branded pharmaceuticals, generic ph...
Burlington, formerly known as Burlington Coat Factory, is an American national off-price retailer, and a division of Burlington Coat Factory Warehouse Corporation with more than 1,138 stores in 46 states and Puerto Rico, with its corporate headquarters located in Burlington Township, New Jersey. In 2007, it was acquired by Bain Capital in a transaction and in 2008, Tom Kingsbury became president and CEO. The company went public again in 2013. Burlington is the third largest off-price retailer...
BHC vs BURL — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2026
| Metric | | |
|---|---|---|
| Revenue | $2.8B | $2.7B |
| Net Profit | $-103.0M | $104.8M |
| Gross Margin | — | 44.2% |
| Operating Margin | 17.0% | 5.1% |
| Net Margin | -3.7% | 3.9% |
| Revenue YoY | 9.3% | 7.1% |
| Net Profit YoY | -205.1% | 15.6% |
| EPS (diluted) | $-0.30 | $1.63 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $2.8B | $2.7B | ||
| Q3 25 | $2.7B | $2.7B | ||
| Q2 25 | $2.5B | $2.5B | ||
| Q1 25 | $2.3B | $3.3B | ||
| Q4 24 | $2.6B | $2.5B | ||
| Q3 24 | $2.5B | $2.5B | ||
| Q2 24 | $2.4B | $2.4B | ||
| Q1 24 | $2.2B | $3.1B |
| Q4 25 | $-103.0M | $104.8M | ||
| Q3 25 | $179.0M | $94.2M | ||
| Q2 25 | $148.0M | $100.8M | ||
| Q1 25 | $-58.0M | $260.8M | ||
| Q4 24 | $98.0M | $90.6M | ||
| Q3 24 | $-85.0M | $73.8M | ||
| Q2 24 | $10.0M | $78.5M | ||
| Q1 24 | $-64.0M | $227.5M |
| Q4 25 | — | 44.2% | ||
| Q3 25 | — | 43.7% | ||
| Q2 25 | — | 43.8% | ||
| Q1 25 | — | 42.9% | ||
| Q4 24 | — | 43.9% | ||
| Q3 24 | — | 42.8% | ||
| Q2 24 | — | 43.5% | ||
| Q1 24 | — | 42.7% |
| Q4 25 | 17.0% | 5.1% | ||
| Q3 25 | 23.1% | 4.7% | ||
| Q2 25 | 17.5% | 5.3% | ||
| Q1 25 | 12.2% | 10.6% | ||
| Q4 24 | 21.8% | 4.7% | ||
| Q3 24 | 12.7% | 4.0% | ||
| Q2 24 | 16.2% | 4.7% | ||
| Q1 24 | 13.1% | 10.0% |
| Q4 25 | -3.7% | 3.9% | ||
| Q3 25 | 6.7% | 3.5% | ||
| Q2 25 | 5.8% | 4.0% | ||
| Q1 25 | -2.6% | 8.0% | ||
| Q4 24 | 3.8% | 3.6% | ||
| Q3 24 | -3.4% | 3.0% | ||
| Q2 24 | 0.4% | 3.3% | ||
| Q1 24 | -3.0% | 7.3% |
| Q4 25 | $-0.30 | $1.63 | ||
| Q3 25 | $0.48 | $1.47 | ||
| Q2 25 | $0.40 | $1.58 | ||
| Q1 25 | $-0.16 | $4.03 | ||
| Q4 24 | $0.24 | $1.40 | ||
| Q3 24 | $-0.23 | $1.15 | ||
| Q2 24 | $0.03 | $1.22 | ||
| Q1 24 | $-0.17 | $3.51 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.3B | $584.1M |
| Total DebtLower is stronger | $20.8B | $2.0B |
| Stockholders' EquityBook value | $-554.0M | $1.5B |
| Total Assets | $26.4B | $9.6B |
| Debt / EquityLower = less leverage | — | 1.32× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $1.3B | $584.1M | ||
| Q3 25 | $1.3B | $747.6M | ||
| Q2 25 | $1.7B | $371.1M | ||
| Q1 25 | $1.1B | $994.7M | ||
| Q4 24 | $1.2B | $857.8M | ||
| Q3 24 | $719.0M | $659.9M | ||
| Q2 24 | $595.0M | $742.3M | ||
| Q1 24 | $733.0M | $925.4M |
| Q4 25 | $20.8B | $2.0B | ||
| Q3 25 | $21.0B | $2.0B | ||
| Q2 25 | $21.7B | $1.6B | ||
| Q1 25 | $21.5B | $1.5B | ||
| Q4 24 | $21.6B | $1.5B | ||
| Q3 24 | $21.5B | $1.2B | ||
| Q2 24 | $21.7B | $1.2B | ||
| Q1 24 | $22.1B | $1.4B |
| Q4 25 | $-554.0M | $1.5B | ||
| Q3 25 | $-565.0M | $1.4B | ||
| Q2 25 | $-764.0M | $1.4B | ||
| Q1 25 | $-1.2B | $1.4B | ||
| Q4 24 | $-1.3B | $1.1B | ||
| Q3 24 | $-1.2B | $1.1B | ||
| Q2 24 | $-1.2B | $1.0B | ||
| Q1 24 | $-1.1B | $996.9M |
| Q4 25 | $26.4B | $9.6B | ||
| Q3 25 | $26.8B | $9.3B | ||
| Q2 25 | $27.3B | $8.5B | ||
| Q1 25 | $26.4B | $8.8B | ||
| Q4 24 | $26.5B | $8.4B | ||
| Q3 24 | $26.5B | $7.8B | ||
| Q2 24 | $26.5B | $7.7B | ||
| Q1 24 | $26.9B | $7.7B |
| Q4 25 | — | 1.32× | ||
| Q3 25 | — | 1.40× | ||
| Q2 25 | — | 1.21× | ||
| Q1 25 | — | 1.12× | ||
| Q4 24 | — | 1.35× | ||
| Q3 24 | — | 1.15× | ||
| Q2 24 | — | 1.20× | ||
| Q1 24 | — | 1.40× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $495.0M | $143.3M |
| Free Cash FlowOCF − Capex | $403.0M | $-109.6M |
| FCF MarginFCF / Revenue | 14.4% | -4.1% |
| Capex IntensityCapex / Revenue | 3.3% | 9.3% |
| Cash ConversionOCF / Net Profit | — | 1.37× |
| TTM Free Cash FlowTrailing 4 quarters | $1.0B | $-358.5M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $495.0M | $143.3M | ||
| Q3 25 | $405.0M | $179.4M | ||
| Q2 25 | $289.0M | $-28.9M | ||
| Q1 25 | $211.0M | $543.2M | ||
| Q4 24 | $601.0M | $110.4M | ||
| Q3 24 | $405.0M | $160.4M | ||
| Q2 24 | $380.0M | $49.4M | ||
| Q1 24 | $211.0M | $598.5M |
| Q4 25 | $403.0M | $-109.6M | ||
| Q3 25 | $314.0M | $-101.0K | ||
| Q2 25 | $190.0M | $-438.6M | ||
| Q1 25 | $96.0M | $189.8M | ||
| Q4 24 | $495.0M | $-56.2M | ||
| Q3 24 | $334.0M | $-35.2M | ||
| Q2 24 | $302.0M | $-115.5M | ||
| Q1 24 | $129.0M | $410.3M |
| Q4 25 | 14.4% | -4.1% | ||
| Q3 25 | 11.7% | -0.0% | ||
| Q2 25 | 7.5% | -17.5% | ||
| Q1 25 | 4.2% | 5.8% | ||
| Q4 24 | 19.3% | -2.2% | ||
| Q3 24 | 13.3% | -1.4% | ||
| Q2 24 | 12.6% | -4.9% | ||
| Q1 24 | 6.0% | 13.1% |
| Q4 25 | 3.3% | 9.3% | ||
| Q3 25 | 3.4% | 6.6% | ||
| Q2 25 | 3.9% | 16.4% | ||
| Q1 25 | 5.1% | 10.8% | ||
| Q4 24 | 4.1% | 6.6% | ||
| Q3 24 | 2.8% | 7.9% | ||
| Q2 24 | 3.2% | 7.0% | ||
| Q1 24 | 3.8% | 6.0% |
| Q4 25 | — | 1.37× | ||
| Q3 25 | 2.26× | 1.91× | ||
| Q2 25 | 1.95× | -0.29× | ||
| Q1 25 | — | 2.08× | ||
| Q4 24 | 6.13× | 1.22× | ||
| Q3 24 | — | 2.18× | ||
| Q2 24 | 38.00× | 0.63× | ||
| Q1 24 | — | 2.63× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BHC
| Bausch Lomb | $1.4B | 50% |
| Salix Segment | $693.0M | 25% |
| International Rx | $306.0M | 11% |
| Diversified Segment | $255.0M | 9% |
| Solta Medical Segment | $137.0M | 5% |
BURL
Segment breakdown not available.
